explore -WSS

explore

author：explore 2025-10-02 22:39:52 - browse：617

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： FDA struggles to regulate food additives, sometimes for decades

WSS

STAT Summit: Biotech founders on deal

The explosion of genetic testing requires a new approach

STAT Summit: Michael J. Fox on progress in Parkinson's research

First Opinion Podcast: Long Covid needs a new approach

UnitedHealth’s board chair also owns a personal investment firm

Beam Therapeutics to lay off 20% of its staff, re

hotspot

explore

hotspot

New air purifier tech could be key to improving indoor air quality

Eating disorder hotline's move to chatbot carried cost for volunteers

Peter Hotez and the public health issue of online harassment

The explosion of genetic testing requires a new approach

How one medical school became remarkably diverse

Supreme Court rules employers must be more accommodating of religious observance

Dobbs anniversary: the lost opportunity of abortion as health care

Eating disorder hotline's move to chatbot carried cost for volunteers

Malaria cases in Florida and Texas: Here’s what you need to know

Pharmacists can make shortage drugs, but at what cost?

explore

Eli Lilly expects to double planned employment in Boston center

Brazil's Jair Bolsonaro is barred from running for office until 2030

STAT Summit: GSK CEO on pharma giant's new direction

Researchers explore possible ties between long Covid, menopause

STAT Readout Newsletter: Today's biggest biotech updates

The explosion of genetic testing requires a new approach

explore

focus

leisure time

focus